Zyprexa (Eli Lilly) Drug Overview & Outlook 2017/18-2026 - ResearchAndMarkets.com

Loading...
Loading...

The "Drug Overview: Zyprexa" report has been added to ResearchAndMarkets.com's offering.

Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Zyprexa: Bipolar Disorder
  4. Zyprexa: Schizophrenia

List of Figures

Figure 1: Zyprexa for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for Zyprexa in bipolar disorder

Figure 3: Drug assessment summary for Zyprexa in bipolar disorder

Figure 4: Zyprexa for schizophrenia - SWOT analysis

Figure 5: Drug assessment summary of Zyprexa for schizophrenia

Figure 6: Drug assessment summary of Zyprexa for schizophrenia

Figure 7: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zyprexa bipolar disorder indication approvals

Table 2: Zyprexa drug profile

Loading...
Loading...

Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder

Table 4: Adverse reactions reported in =5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)

Table 5: Key side effects reported in clinical trials of Zyprexa in bipolar disorder

Table 6: Zyprexa drug profile

Table 7: Zyprexa pivotal trial data in schizophrenia

Table 8: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country M, 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/hhmvmg/zyprexa_eli?w=4

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...